JP7813235B2 - NPM1c陽性がんの免疫療法のための組成物および方法 - Google Patents

NPM1c陽性がんの免疫療法のための組成物および方法

Info

Publication number
JP7813235B2
JP7813235B2 JP2022553053A JP2022553053A JP7813235B2 JP 7813235 B2 JP7813235 B2 JP 7813235B2 JP 2022553053 A JP2022553053 A JP 2022553053A JP 2022553053 A JP2022553053 A JP 2022553053A JP 7813235 B2 JP7813235 B2 JP 7813235B2
Authority
JP
Japan
Prior art keywords
antigen
antibody
cells
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022553053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517889A5 (cg-RX-API-DMAC7.html
JP2023517889A (ja
Inventor
チェン,ジャンツ
シェ,グゥオツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2023517889A publication Critical patent/JP2023517889A/ja
Publication of JP2023517889A5 publication Critical patent/JP2023517889A5/ja
Priority to JP2026014397A priority Critical patent/JP2026094130A/ja
Application granted granted Critical
Publication of JP7813235B2 publication Critical patent/JP7813235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022553053A 2020-03-10 2021-01-08 NPM1c陽性がんの免疫療法のための組成物および方法 Active JP7813235B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026014397A JP2026094130A (ja) 2020-03-10 2026-01-30 NPM1c陽性がんの免疫療法のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062987612P 2020-03-10 2020-03-10
US62/987,612 2020-03-10
PCT/US2021/012701 WO2021183207A1 (en) 2020-03-10 2021-01-08 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026014397A Division JP2026094130A (ja) 2020-03-10 2026-01-30 NPM1c陽性がんの免疫療法のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023517889A JP2023517889A (ja) 2023-04-27
JP2023517889A5 JP2023517889A5 (cg-RX-API-DMAC7.html) 2024-01-16
JP7813235B2 true JP7813235B2 (ja) 2026-02-12

Family

ID=75888143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022553053A Active JP7813235B2 (ja) 2020-03-10 2021-01-08 NPM1c陽性がんの免疫療法のための組成物および方法
JP2026014397A Pending JP2026094130A (ja) 2020-03-10 2026-01-30 NPM1c陽性がんの免疫療法のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026014397A Pending JP2026094130A (ja) 2020-03-10 2026-01-30 NPM1c陽性がんの免疫療法のための組成物および方法

Country Status (11)

Country Link
US (1) US11896619B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118112A1 (cg-RX-API-DMAC7.html)
JP (2) JP7813235B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167276A (cg-RX-API-DMAC7.html)
CN (1) CN115485295A (cg-RX-API-DMAC7.html)
AU (1) AU2021232853A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017924A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173981A1 (cg-RX-API-DMAC7.html)
IL (1) IL296241A (cg-RX-API-DMAC7.html)
MX (1) MX2022011178A (cg-RX-API-DMAC7.html)
WO (1) WO2021183207A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212632A2 (en) * 2022-04-27 2023-11-02 The Children's Medical Center Corporation Anti-nucleophosmin 1 antibody and antibody conjugate combination therapies
EP4514858A4 (en) * 2022-04-27 2026-08-12 Childrens Medical Ct Corp MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMINE 1 USED AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2019004831A1 (en) 2017-06-30 2019-01-03 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US884088A (en) 1907-02-16 1908-04-07 John C Hendrickson Combined register backing and damper.
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004043401A2 (en) 2002-11-13 2004-05-27 Wackvom Limited Method of preparing anti-angiogenic drug from cartillage and chondrocytes and methods of use
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8007796B2 (en) 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DE102006031054B4 (de) 2006-07-05 2010-08-05 Hänel & Co. Hochregal mit Lagergutanwahl
JP5297805B2 (ja) 2006-07-31 2013-09-25 株式会社ダイキン ポリエステルの難燃化処理剤とこれを用いた難燃化処理方法
US9334330B2 (en) 2006-10-10 2016-05-10 Universite De Nantes Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
WO2008099188A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
US20110038836A1 (en) 2007-04-23 2011-02-17 The Board Of Regents, The University Of Texas System Device and Method for Transfecting Cells for Therapeutic Use
US20110213288A1 (en) 2007-04-23 2011-09-01 The Board Of Regents, The University Of Texas System Device And Method For Transfecting Cells For Therapeutic Uses
US7468685B1 (en) 2007-08-20 2008-12-23 Fairchild Semiconductor Corporation Clockless serialization using delay circuits
DE102007042151A1 (de) 2007-09-05 2009-03-12 Manroland Ag Druckmaschine
WO2010015881A1 (en) 2008-08-05 2010-02-11 Mehdy Davary Dolat Abady Position encoding using an invisible pattern data matrix
CN101335956B (zh) 2008-08-05 2011-10-05 国民技术股份有限公司 借助误码率统计数据判断通信距离的系统和方法
WO2010017827A1 (en) 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
WO2010029597A1 (ja) 2008-09-10 2010-03-18 株式会社アドバンテスト 試験装置および回路システム
EP2169837B1 (en) 2008-09-29 2013-01-30 Telefonaktiebolaget LM Ericsson (publ) Technique for suppressing noise in a transmitter device
US20100322909A1 (en) 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
CN101998390B (zh) 2009-08-27 2015-03-25 华为技术有限公司 保证通信安全的方法及设备
IT1395561B1 (it) 2009-09-03 2012-09-28 Applied Materials Inc Apparato di collaudo e relativo procedimento
ES2619937T3 (es) 2009-10-27 2017-06-27 Delta-Fly Pharma, Inc. Nuevo derivado de 5-fluorouracilo
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20110104128A1 (en) 2009-10-30 2011-05-05 The Board Of Regents, The University Of Texas System Device and Method for Transfecting Cells for Therapeutic Use
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011150420A1 (en) 2010-05-28 2011-12-01 Baylor College Of Medicine Modified gold nanoparticles for therapy
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
WO2012012695A2 (en) 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
US20120029577A1 (en) 2010-07-28 2012-02-02 Sean Kerr System and method for bone fixation using biodegradable screw having radial cutouts
WO2012021378A2 (en) 2010-08-09 2012-02-16 Ellipse Technologies, Inc. Maintenance feature in magnetic implant
WO2012023096A2 (en) 2010-08-19 2012-02-23 Koninklijke Philips Electronics N.V. Oled-mirror-element and oled-mirror-device
WO2012136231A1 (en) 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
CA2816379A1 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
WO2012071420A1 (en) 2010-11-23 2012-05-31 The Trustees Of Columbia University In The City Of New York Enzyme combinations to reduce brain tissue swelling
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
KR101796322B1 (ko) 2011-01-07 2017-12-01 삼성전자주식회사 항법 알고리즘을 이용한 위치 정보 검출 장치 및 방법
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
EA201401134A1 (ru) 2011-02-11 2015-05-29 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2012148552A2 (en) 2011-02-24 2012-11-01 The Research Foundation Of State University Of New York Rectifying electromagnetic nanosensors
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
GB201108236D0 (en) 2011-05-17 2011-06-29 Ucl Business Plc Method
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US8740931B2 (en) 2011-08-05 2014-06-03 Merit Medical Systems, Inc. Vascular filter
WO2013027420A1 (ja) 2011-08-24 2013-02-28 パナソニック株式会社 フォーカルプレーンシャッタ装置および撮像装置
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
JP6074435B2 (ja) 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US8772058B2 (en) 2012-02-02 2014-07-08 Harris Corporation Method for making a redistributed wafer using transferrable redistribution layers
CN104105715B (zh) 2012-02-13 2016-05-11 电化株式会社 氯丁二烯橡胶组合物、使用该氯丁二烯橡胶组合物的粘合剂组合物
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
KR20210149195A (ko) 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 t 세포의 투여 적합성을 평가하는 방법
US9185235B2 (en) 2012-08-02 2015-11-10 Ab Initio Technology Llc Aggregating data in a mediation system
JP5822798B2 (ja) 2012-08-08 2015-11-24 三菱電機株式会社 断熱箱体及びこの断熱箱体を備えた冷蔵庫
US20140065629A1 (en) 2012-08-29 2014-03-06 Israel Barken Methods of treating diseases
WO2014032253A1 (zh) 2012-08-30 2014-03-06 海能达通信股份有限公司 压控震荡电路和无线通信设备
US11471486B2 (en) 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
EP2893080A1 (en) 2012-09-04 2015-07-15 RTE Technologie GmbH Locating pin arrangement for aligning railway slabs on a base plate
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2893566B1 (fr) 2012-09-05 2016-05-18 Institut National des Sciences Appliquées de Lyon Procede de fabrication d'un transistor a effet de champ a jonction jfet
WO2014049581A2 (en) * 2012-09-28 2014-04-03 Jawaharlal Nehru Centre For Advanced Scientific Research Monoclonal antibodies against npm1 and acetylated npm1, methods and kit thereof
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014059248A1 (en) 2012-10-12 2014-04-17 Philadelphia Health & Education Corporation D/B/A/ Drexel Mir-155 enhancement of cd8+ t cell immunity
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US20140274801A1 (en) 2013-03-14 2014-09-18 Elwha Llc Compositions, methods, and computer systems related to making and administering modified t cells
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3461491B1 (en) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
CN105431456A (zh) 2013-06-14 2016-03-23 休斯敦系统大学 用修饰的嵌合抗原受体靶向肿瘤新生血管
DE102013212604A1 (de) 2013-06-28 2014-12-31 Robert Bosch Gmbh Bearbeitungswerkzeug
EP3021853A1 (en) 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
NO335489B1 (no) 2013-08-27 2014-12-22 Langåker John Magne Multifunksjons varmepumpe
EP3039829B1 (en) 2013-08-30 2020-03-25 Hubbell Incorporated Wifi hazardous area voip paging telephone
WO2015038684A1 (en) 2013-09-10 2015-03-19 Polyera Corporation Attachable article with signaling, split display and messaging features
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR20160120301A (ko) 2014-02-05 2016-10-17 엘코겐 오와이 전지 시스템용 조립 방법과 배열체
US9926405B2 (en) 2014-03-17 2018-03-27 Namics Corporation Resin composition
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的NKp46結合タンパク質
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN104894068A (zh) 2015-05-04 2015-09-09 南京凯地生物科技有限公司 一种利用CRISPR/Cas9制备CAR-T细胞的方法
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CA3007898A1 (en) 2015-12-28 2017-07-06 Innate Pharma Variable regions for nkp46 binding proteins
CN106399375A (zh) 2016-08-31 2017-02-15 南京凯地生物科技有限公司 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
CN106480097A (zh) 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
CN106591363A (zh) 2016-11-11 2017-04-26 广东万海细胞生物科技有限公司 一种通用型异体car‑t细胞制备方法及应用
CN106755088A (zh) 2016-11-11 2017-05-31 广东万海细胞生物科技有限公司 一种自体car‑t细胞制备方法及应用
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2019004831A1 (en) 2017-06-30 2019-01-03 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Also Published As

Publication number Publication date
WO2021183207A1 (en) 2021-09-16
MX2022011178A (es) 2023-01-04
CA3173981A1 (en) 2021-09-16
US20210283178A1 (en) 2021-09-16
JP2026094130A (ja) 2026-06-09
JP2023517889A (ja) 2023-04-27
CN115485295A (zh) 2022-12-16
IL296241A (en) 2022-11-01
US11896619B2 (en) 2024-02-13
KR20220167276A (ko) 2022-12-20
AU2021232853A1 (en) 2022-09-22
EP4118112A1 (en) 2023-01-18
BR112022017924A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
JP7793001B2 (ja) 抗ccr8抗体及びその使用
JP7587858B2 (ja) ヒトcd137に結合するアゴニスト性抗体およびその使用
ES2991026T3 (es) Anticuerpos de cadena pesada (VHH) contra claudina 18A2 y uso de los mismos
KR102411490B1 (ko) Cd39에 결합하는 항체 및 이의 용도
US20250313645A1 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
KR20180077193A (ko) 예후 방법
KR20230147624A (ko) 면역조절 항체 및 이의 용도
US11896619B2 (en) Compositions and methods for immunotherapy of NPM1c-positive cancer
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
HK40084778A (en) Compositions and methods for immunotherapy of npm1c-positive cancer
HK40102183A (en) Non-blocking human ccr8 binders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260130

R150 Certificate of patent or registration of utility model

Ref document number: 7813235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150